WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.

A former manager at Merck has opened his own Seniors Helping Seniors franchise in Philadelphia with plans to hire 100 senior ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would limit business for Chinese biotech companies ...

Truist downgraded Merck (MRK) to Hold from Buy with a price target of $110, down from $130, as part of a broader research note previewing FY25 for large-cap biopharma. The sector has ...

China's WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom January 6, 2025 Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million. The Financial Times had reported in October that WuXi and WuXi ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate ...

The Chinese contract drugmaker will sell its vaccine factory in Dundalk, Ireland, to U.S.-based Merck for about $500 million, it said in an exchange filing late Monday. The facility, with a net ...